(AOF) – As part of its strategic evolution focused on the development of new processes favoring in particular the development of biotherapies, Hybrigenics SA announced the appointment, during the Board of Directors meeting of January 6, 2022, of Léone Atayi to the General Management of the society.
Léone Atayi has worked for more than ten years in the field of biotechnology and the pharmaceutical industry. She notably held the position of Administrative and Financial Director within a world leader in transfection reagents, consumables used for the production of cell and gene therapies in strong growth, of which she was also a shareholder and member of the Board of Directors. .
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an unprecedented amount of credits (7 billion euros): 1.5 billion for university hospital research, 2 billion for investment in health via bpi France , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenses reimbursed by Medicare will be 2.4%, which should generate at least 0.5% growth in laboratory turnover,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the actual benefit is sufficient.